Medical Communications
Anti-inflammatory baricitinib is a life-saving COVID-19 drug
March 4, 2022 Medical Communications
UK experts say they have identified another life-saving drug that can alleviate COVID-19 illness. The anti-inflammatory baricitinib is usually used …
Risk of hospitalisation five times higher with J&J
March 3, 2022 Business Services, Medical Communications
A study published in Jama Network Open has revealed that Johnson & Johnson’s coronavirus vaccine was far less effective at …
FDA grants breakthrough therapy designation to RSV vaccine
March 3, 2022 Business Services, Medical Communications
The FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, for the prevention of …
WHO recommends Merck’s COVID-19 pill
March 3, 2022 Business Services, Medical Communications
WHO have recommended Merck’s pill, molnupiravir, for the treatment of COVID-19 in patients in high risk groups, such as the …
Study reveals potential genetic determinants of unexplained child deaths
February 25, 2022 Medical Communications
Various genetic determinants may cause a predisposition to Sudden Unexpected Death in Paediatrics (SUPD), which encompasses syndromes such as Sudden …
NICE draft guidance recommends tucatinib for advanced breast cancer
February 25, 2022 Medical Communications
Roughly 400 people with advanced breast cancer are set to benefit from a new treatment, following the NICE publication of …
CHMP recommends QUVIVIQ in Europe as a new treatment for adult insomnia patients
February 25, 2022 Medical Communications
The CHMP has adopted a positive opinion for the use of QUVIVIQ for the treatment of adult patients with insomnia. …
Plant-based COVID-19 vaccine approved
February 25, 2022 Medical Communications
Medicago and GlaxoSmithKline (GSK) have announced the approval by Health Canada of COVIFENZ®, a COVID-19 vaccine manufactured in plants, with …
Study shows antibiotics affect gut microbes of newborns
February 18, 2022 Medical Communications
Researchers from the Universities of Edinburgh and Birmingham, with the Spaarne Hospital and University Medical Centre Utrecht, Netherlands, have conducted …
Pfizer and BioNTech Omicron vaccine delayed
February 18, 2022 Medical Communications
The delivery of Pfizer and BioNTech SE’s vaccine, targeted specifically towards the Omicron COVID-19 variant has been delayed by several …
NHS bosses call for free COVID-19 tests and isolation to remain
February 18, 2022 Medical Communications
NHS bosses have called for free COVID-19 testing to remain, in spite of speculation that this could be scrapped. Boris …
Trial paused for respiratory virus vaccine in pregnant women
February 18, 2022 Medical Communications
GlaxoSmithKline (GSK) has hit pause on a Phase III clinical trial on safety grounds. The late-stage trial for GSK’s vaccine …
Astellas and Seagen announce results of study into muscle-invasive bladder cancer
February 15, 2022 Medical Communications
Astellas Pharma and Seagen announced the initial results from Cohort H of their EV-103 trial. This investigated PADDCEV (enfortumab vedotin-ejfv) …
NICE recommends new diagnostic devices for men with suspected prostate cancer
February 15, 2022 Medical Communications
NICE have recommended four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related …
Risk of new heart problems raised after COVID-19
February 11, 2022 Medical Communications
A large study has found that long after recovery from COVID-19, people continue to face significantly higher risks for new …
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
October 26, 2026
